Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Quitting Matters: a smoking quit program for people living with HIV

Official title: Hybrid Trial of a Digital Therapeutic for Smoking Cessation Among Persons Living With HIV

Run by Wake Forest University Health Sciences · NCT06883097 · Data updated 2026-11-12

This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment314 (estimated)
SponsorWake Forest University Health Sciences
Academic / other
Locations1 site (Winston-Salem, North Carolina)
StatusRecruiting
StartedAugust 18, 2025
Main results expectedSeptember 2028
Study endsSeptember 2028
Registry record updatedSeptember 30, 2026
Trial IDNCT06883097 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal participants are adults (18+) living with HIV who smoke daily, want to quit, are currently in HIV care, can use NRT, and own an Android or iOS smartphone.

Probably not a fit

People who are pregnant, currently receiving other smoking-cessation treatments, medically ineligible for NRT, not fluent in English, or who cannot use a smartphone are unlikely to benefit from this program.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants who smoke and are receiving HIV care will be randomized to use one of two smartphone smoking-cessation apps for about 24 weeks while receiving nicotine replacement therapy (patches and gum). The trial includes five video-call visits during which staff collect questionnaires, interviews, and breath or saliva samples to measure smoking outcomes. One app is specifically tailored for people with HIV and the other is a general quit app, allowing comparison of effectiveness and implementation barriers. The study also documents feasibility and factors that affect adoption of digital therapeutics in this population.

Why it matters

Potential benefit: If successful, a tailored app plus NRT could increase quit rates among people living with HIV and reduce smoking-related illness in this group.

How similar studies have gone: Digital smoking-cessation apps have shown effectiveness in the general population, but large trials of tailored apps for people with HIV are lacking.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Self-reported daily cigarette smoking over the past 30 days
2. Self-reported HIV status
3. Age 18 or older
4. Desire to quit smoking
5. Willing and medically eligible to use NRT
6. Currently receiving HIV care
7. Currently owning an Android or iOS smartphone

Exclusion Criteria:

1. Current acute psychotic episode or unsafe to participate in the study
2. Pregnant or intending to become pregnant in the next 6 months
3. Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation
4. Any medical condition or medication that could compromise subject safety, as determined by the PIs and/or study physician
5. Not able to fluently speak and write in English
6. Hearing, comprehension, visual, speech, or motor limitations that preclude study participation

Where it's running

  • Wake Forest University, Implementation Science
    Winston-Salem, North Carolina, United States
    Recruiting

Study contacts

  • Principal investigator: Roger Vilardaga Viera, Ph.D. — Wake Forest University Health Sciences
  • Study coordinator: Roger Vilardaga Vierra, Ph.D.
  • Email: Roger.Vilardaga@wfusm.edu
  • Phone: 336-716-1495

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.